Method for diminishing ulcerogenic effect of solid medicinal formulation of stomach mucosa

FIELD: medicine, therapy, gastroenterology, pharmacy.

SUBSTANCE: method involves oral intake of solid medicinal formulation at vertical position of patient and change of medicinal formulation position into stomach is carried out in each 5 min, not rare. Change of medicinal formulation position is carried out by pressing on epigastrium region by hand or by cyclic change of position of patient body from its vertical position to horizontal position and back. Method provides enhancing safety in enteral using a solid medicinal formulation due to diminishing its ulcerogenic effect. Invention can be used in enteral using solid medicinal formulations.

EFFECT: improved method for diminishing ulcerogenic effect.

2 ex

 

The invention relates to medicine, in particular to therapy, and can be used for enteral application of solid dosage forms, especially steroid or non-steroidal anti-inflammatory drug, a dangerous probability of ulcerogenic effects on the stomach.

A known way to reduce the ulcerogenic action of acetylsalicylic acid by assigning it with sodium bicarbonate (Gayova PPM, Galenko-Jaroszewski P.A., Petrov V.I. Pharmacotherapy with the basics of clinical pharmacology. Ed. Vietrova. Volgograd. 1996. - S.312).

The disadvantage of this method is that in case of simultaneous administration of either drug is not achieved protection of gastric mucosa from the ulcerogenic action of solid dosage forms, which, regardless of the presence of sodium bicarbonate falls on the lower part of the stomach and it remains motionless, where during the period of dissolution time to produce excessive irritation or cauterizing effect, which can lead to erosion and ulcers of the mucous membrane in the place of their contact with each other.

In addition, sodium bicarbonate may be quickly absorbed into the bloodstream and provide system exert alkaline action until the development of systemic alkalosis, which may lead to hypercalcemia with nephrocalcinosis and renal insufficient the flesh.

There is a method of reducing negative impacts tablets of aspirin on the gastric mucosa by assigning it with food and the use of liquid or buffered dosage forms (Graham-Smith became popular, Aronson JK Oxford Handbook of clinical pharmacology and pharmacotherapy. TRANS. from English. - M.: Medicine. - 2000. - Pp.481).

The disadvantage of this method is the high probability of ulcer formation due to ulcerogenic actions of a solid dosage form to the mucosal surface of the stomach, because the tablet has a higher specific gravity, therefore, falls on the lower part of the stomach, where during the period of dissolution has a cauterizing action in place of its contact with the mucous membrane, leading to ulcers.

The purpose of the invention is improving the safety of enteral application of solid dosage forms by reducing ulcerogenic actions.

The essence of the proposed method reduce ulcerogenic of the solid dosage forms in the lining of the stomach, including its oral administration in a vertical position the patient's torso, is that in subsequent periodically change the position of the tablet inside the stomach. To offset medications vertical position of the torso lean hand on the epigastric region or change position'toole is the highest, translating it from the vertical to the horizontal, lying on his back, returning again in the vertical, repeating the cycle with a delay at each position not more than 5 minutes.

Periodic changing of position of the dosage forms inside the stomach prevents excessive contact with any one part of the mucous membrane of the stomach, which increases the safety of enteral application of solid dosage forms by reducing ulcerogenic actions.

Short-term (no more than 5 minutes) to find a tablet or other solid dosage forms in each new location eliminates the development of chemical burns in the contact and the formation of ulcers.

The method is as follows. Take the tablet or other solid dosage form in an upright position of the body and the fingers or palm of the hand periodically, at least every 5 minutes, press on the epigastric region or periodically change the position of the trunk, turning it from a vertical to a horizontal position, lying on his back, coming back to a vertical position, with the delay at each position not more than 5 minutes, repeating the cycle until complete dissolution of the tablets in gastric juice, the duration of which is known from the passport accompanying each series cardgamepokervideo medicines.

Examples

Patient H., 52 years was admitted to the medical unit with a diagnosis of Coronary heart disease: stable angina, functional class II. During the three weeks of the baseline therapy with the inclusion of a tablet of aspirin in a dose of 100 mg per day, taken in a vertical torso, once in the morning. To reduce the ulcerogenic action tabletiruemogo aspirin patient was recommended after each use every 5 minutes twice change the position of the torso, cyclically translating it from a sitting position on the bed in the supine position. By the end of treatment fibrogastroskopicheski confirmed the absence of erosion, ulceration in the stomach, and the patient was discharged in good condition.

The Century patient, 53 years of age was admitted to the medical unit with a diagnosis of Bronchial asthma mixed variant, severe, acute phase. Respiratory failure II. During the four weeks of the baseline therapy with the inclusion of enteric pills prednisolone at a dose of 20 mg per day. To reduce the ulcerogenic action of prednisolone tablets taken in a vertical torso of the patient (sitting in bed), he was recommended after each use prednisolone for 20 minutes each is 1. 2. 3 or 5 minutes periodically to press the hand on the epigastric region. By the end of the treatment fibrogastroskopicheski confirmed the absence of erosions and ulcers in the lining of the stomach, and the patient was discharged in good condition.

Thus, the proposed method allows to reduce the ulcerogenic action of tablet dosage forms when the enteral intake with vertical position of the patient's torso such azwoobrazovania medicines, such as aspirin and prednisolone. In addition, changing the position of the tablets inside the stomach due to pressure on oblasti epigastria can be used in the treatment of patients, forced to reside in a fixed horizontal position (injured, paralyzed, and others).

1. The way to reduce the ulcerogenic action of solid dosage forms in the lining of the stomach, including its oral administration in a vertical position the patient's torso, wherein periodically at least every 5 min modifies provisions dosage forms inside the stomach.

2. The method according to claim 1, wherein changing the position of the solid dosage form is produced by pressing with a hand on the epigastric region.

3. The method according to claim 1, wherein changing the position of the solid dosage form of product is drawn by the cyclic changes of the torso of the patient, turning it from a vertical to a horizontal position and Vice versa.



 

Same patents:

FIELD: medicine, stomatology.

SUBSTANCE: the present innovation deals with applying means for oral hygiene. The suggested tooth paste contains chromatic component, foaming agent, abrasive component, binding substance, additionally, it contains moisturizing agents, conservants, biological additives and aromatizing agents, moreover, as a chromatic component one should apply dietary dyestuff or juices or extracts of berries and vegetables applied in food industry for tinting: components should be taken at certain quantitative content. Tooth paste enables to control the degree of oral purification and perform diagnostics of caries at its earlier stages to detect microfissures and dental calculus.

EFFECT: higher efficiency of application.

2 cl, 3 ex

FIELD: prosthetic dentistry, in particular removable bridgework.

SUBSTANCE: claimed composition is made of polyvinylchloride resin powder, liquid dioctylphtalate, epoxydized soy oil and additionally calcium stearate as stabilizer. Powder and liquid are blended, 70-80 % of obtained mixture is added to earlier mixed powder, obtained mass is heated at 60-80°C for 13-15 min, and residual (20-30 %) liquid plasticizer with epoxydized soy oil are added to formed mass. Further mass is packed together with paste of basic plastic, pressed and conditioned at 65°C, then obtained product is heated up to 170°C for 2 h and conditioned for 50-60 min. Then form with ferrule is cooled to room temperature.

EFFECT: removable dental prosthesis of improved quality.

5 ex, 1 tbl, 2 cl

FIELD: medicine.

SUBSTANCE: method involves administering autohemotherapy in addition to generally applied medical treatment. Homeopathic remedy is added in the amount of 2.2-3.3 ml to 2-4 patient blood drops. The mixture is shaken up and a half of this quantity is intramuscularly injected. Then, the same homeopathic remedy is repeatedly added to the mixture that is shaken up and introduced along transition fold under patient gingival papillae. The homeopathic remedy is selected in accordance with concomitant patient diseases.

EFFECT: enhanced effectiveness of treatment.

3 cl

FIELD: medicine, stomatology, pharmaceutical industry.

SUBSTANCE: invention relates, in particular, to a method for preparing agent used in treatment of parodontium. Method for preparing an agent used for treatment of parodontium involves milling the following vegetable raw - bird cherry fruits, horse radish roots, clove tree flower buds, ginger rhizomes up to the definite size of particles, infusing raw in 70% ethanol, successive extraction of raw with ethanol by percolation method under definite conditions followed by addition of essential oil taken in the definite amount to combined extracts. Agent promotes to the effective treatment of parodontium.

EFFECT: improved preparing method, valuable medicinal properties of agent.

2 ex

FIELD: medicine, stomatology.

SUBSTANCE: invention relates to agents used for teeth cleansing and a method for their preparing. Composition for mouth cavity comprises an orally acceptable carrier containing complex formed in carrier and consisting of zinc salt, anionic polycarboxylate polymer and pyrophosphate salt. Method for preparing the stable composition involves preparing a carrier acceptable for mouth cavity and moistening agents and mixing a carrier with zinc salt, anionic polycarboxylate polymer and pyrophosphate salt to form the complex zinc/anionic polycarboxylate/pyrophosphate. Method provides preparing the stable composition that allows removing unpleasant mouth odor and elicits improved taste indices in using.

EFFECT: improved and valuable properties of agent.

14 cl, 1 tbl, 1 ex

FIELD: medicine, stomatology.

SUBSTANCE: one should inject richlocaine simultaneously as irrigations of mouth cavity, as applications onto gingival mucosa and into gingival pouches, as gingival electrophoresis and submucous injection in therapeutic dosages. The present innovation enables to prolong remission terms and decrease the number of disease relapses due to stabilizing pathological processes in parodontium tissues.

EFFECT: higher efficiency of therapy.

1 ex, 5 tbl

FIELD: stomatology and pharmaceutical industry.

SUBSTANCE: agent represents oil or oil extract obtained from annual sweet pepper comprising tocopherol, carotinoids, phospholipids, and fraction of free and bound acids containing at least 13% saturated acids, at least 7% monounsaturated acids, and at least 60% polyunsaturated acids, as well as fraction of non-hydrolyzed residue containing sterols (23-40% of β-sitosterol) and triterpene alcohols. Clinical tests have shown good tolerance of agent at absence of toxicity and allergic reactions.

EFFECT: Reduced treatment time by 4-10 days.

6 tbl

FIELD: stomatology, in particular agents for buccal cavity healthcare.

SUBSTANCE: claimed composition contains potassium-aluminum sulfate, anticoagulation agent, selected from alkali metals, sodium tetraborate, Trilone B, week carboxylic acid, sodium benzoate, succinic acid, flavor, sweetener, food-grade dye and water in specific quantitative ratio.

EFFECT: agent with wide range of antimicrobial action, deodorization and haemostatic effects.

4 cl, 2 tbl

FIELD: stomatology.

SUBSTANCE: tooth root canal filling composition effective in cases of periodontitis and parodontosis contains zinc oxide, resorcinol, formalin, and additionally thymol, all taken is specified proportions. Composition allows treatment of periodontitis and parodontosis with elevated tooth mobility and without change in solid dental tissue color.

EFFECT: increased treatment efficiency and simultaneously antiseptic and bactericidal properties.

FIELD: medicine, stomatology.

SUBSTANCE: the present innovation deals with taking care of one's mouth cavity. The suggested composition contains a silicone polymer, silicone resin, nonvolatile liquid polysiloxane and, also, an active substance for taking care of mouth cavity, a volatile solvent of either organic or silicone origin at its boiling point being 200 C, or lower at the pressure of 1 atm. This composition provides prolonged release of active substance.

EFFECT: higher prophylactic and therapeutic action.

18 cl, 8 ex, 8 tbl

FIELD: medicine, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to a method for pressing in preparing a medicinal formulation of phenytoin sodium, method for pressing in rollers and preparing a pharmaceutical composition involves stages of addition of phenytoin sodium into a mixer receiver and addition of at least one excipient into indicated mixer. Mixture is stirred and transferred into roller thickener wherein pressure is applied on the mixture of phenytoin sodium and excipient. The prepared compact-(briquette) is ground and prepared granulate is mixed repeatedly that is suitable from further processing to a medicinal formulation. Excipients involve magnesium stearate, sugar, lactose monohydrate and talc, or talc is added directly before the second mixing the granulate.

EFFECT: improved pressing method.

15 cl, 10 tbl, 2 dwg, 4 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to agents stimulating the central nervous system, i. e. psychomotor stimulators. Invention proposes combination of sydnocarbum with ladastenum taken in the ratio = 1:(0.4-2) as an agent. Invention provides enhancing physical working ability, prevents the development of acute physical fatigue and exceeds effect of sydnocarbum and ladastenum by 2.7 and 1.6 times, respectively.

EFFECT: enhanced effectiveness and valuable medicinal properties of agent.

4 cl, 13 tbl

FIELD: medicine, psychiatry, pharmacy.

SUBSTANCE: invention relates to the orally decomposition composition comprising mirtazapine. A single dosed medicinal formulation decomposing rapidly after its oral administration is bioequivalent to usual tablet but shows advantages with respect to adverse effects, effectiveness, anxiolytic effects, dream-improving effects, and acceleration of onset effect of an antidepressant agent. Invention can be used in treatment of depression.

EFFECT: valuable medicinal and pharmaceutical properties of composition.

5 cl, 1 tbl, 2 ex

FIELD: chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to manufacturing solid medicinal formulations of preparations. Invention proposes a medicinal formulation consisting of a core comprising the following components: indometacin, lactose, calcium phosphate, hydroxypropylcellulose, magnesium stearate, sodium croscarmellose and envelope comprising collicute MAE 100P, propylene glycol, pigment titanium dioxide, talc, collidon-30, brown sycovite-70. Also, invention discloses a method for preparing the formulation. Invention provides enhancing stability of envelope to effect of stomach juice, rapid and complete release of active substance, simultaneous simplifying the process of applying the envelope for a single step.

EFFECT: improved and valuable pharmaceutical properties of formulation.

3 cl, 1 tbl

FIELD: medicine, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to a solid medicinal formulation eliciting an antihypertensive, anti-anginal, vasodilating, antioxidant and antiproliferative effect. The solid medicinal formulation comprises the following components: carvedilol, disaccharide, magnesium stearate, starch, calcium phosphate, hydroxypropylmethylcellulose, aerosil and carboxymethylcellulose sodium salt. Also, invention discloses a method for preparing this formulation. Invention provides preparing the formulation eliciting high rate and fullness in releasing an active substance in the human body, stability of quality indices for all fitness period and allowing the effective usage in manufacturing the medicinal agent. Invention can be used in treatment hypertension, stenocardia, myocardium ischemia and chronic cardiac insufficiency.

EFFECT: improved preparing method, valuable medicinal properties of formulation.

5 cl, 1 tbl, 4 ex

FIELD: chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to a new pharmaceutical composition comprising benzamide derivative and one or some additives taken among the following substances: 1) mixture of polyethylene glycol and surface-active substance; 2) amino acid or inorganic acid salt, and 3) propylene carbonate. The composition comprises benzamide derivative taken in the amount from 0.001 to 1000 mg per a single dosing formulation. The composition shows the enhanced solubility and absorption capacity in oral route of administration.

EFFECT: improved medicinal and pharmaceutical properties of composition.

9 cl, 4 tbl, 1 dwg, 5 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a solid pharmaceutical composition. The composition comprises tegaserod or its salts as an active component that is sensitive to acid effect and/or difficultly soluble in water, and a loosening agent taken in the amount at least 15 wt.-% as measured for the total mass of the composition. The composition is stable and can be prepared easily, it shows good rate release after its administration patients and good biological availability. The composition is designated for prophylaxis, modulation or treatment of visceral pain or discomfort, for modulation of visceral sensitivity or perception, improvement of sensory perception of rectum intestine tension and for treatment of anal dysfunction regulation.

EFFECT: improved and valuable medicinal properties of composition.

14 cl, 7 ex

FIELD: medicine, chemical-pharmaceutical industry.

SUBSTANCE: invention relates to a method for making compositions as carbonated tablets. Method involves granulation, drying, calibration, powdering and tableting. Method involves using anhydrous components and powder of each component is dried preliminary for 1 h, not less, at temperature below the decomposition point. Then powder components of active agent, basic and acid components providing the carbonated property are mixed being involving, if necessary, components of neutral substances, sweetening agents and special additives. Prepared mixture is granulated with 7-20% solution of a binding agent in isopropyl alcohol or ethanol and then the prepared granulate is dried at temperature not resulting to deterioration of granulate properties, to residual moisture 0.1-0.3%. Then method involves calibration of granules up to the size 1000-1200 mcm, powdering the prepared tablet mass and its tableting in moisture value of environment medium 5-25%. Invention provides reducing duration and labor intensity of the method due to exclusion the necessity carrying out the separate granulation of components and the development of technology providing the possibility for carrying out a single-step combined granulation of all components of the composition. Simplifying and acceleration of the method are attained in retention of high quality of ready tablets.

EFFECT: improved preparing method.

14 cl, 7 ex

FIELD: chemical-pharmaceutical industry and technology, pharmacy.

SUBSTANCE: omeprazole is a strong anti-ulcer agent that is absorbed in intestine preferably but it unstable in acid medium. Some methods for preparing stable pharmaceutical compositions and solution of two main problems of effect on their stability, pH and moisture, have been studied. Invention describes a method for preparing pharmaceutical composition as tablet formulation comprising omeprazole, sodium alginate and basic amino acid and involving following steps: (a) preliminary modification of external morphology of basic amino acid by wetting and the following drying up to the water content in the total amount less 0.75 wt.-% of amino acid mass; (b) incorporation of basic amino acid to preliminary prepared granulate comprising omeprazole and sodium alginate with the low moisture content; (c) incorporation of other excipients up to preparing granulate; (d) grinding granulate from step (c) up to preparing uniform granulometric composite; (e) incorporation of lubricating agent, carrying out the tableting process and applying enterosoluble coating on tablets made. Such method is simpler as compared with known ones and provides preparing compositions with improved indices of extrusion. The content of sodium alginate can up to 15 wt.-% of tablet mass, preferably, from 8 to 12 wt.-%. Basic amino acid can represent L-arginine, L-lysine or L-histidine. Pharmaceutical compositions prepared by this method comprise omeprazole in concentrations 10-40 mg per a tablet.

EFFECT: improved preparing method.

6 cl, 4 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a new composition of benzimidazole (omeprazole) and a method for its preparing. The benzimidazole composition comprises a benzimidazole compound in common with compound with acid reaction and includes inert core with applied benzimidazole, inert and external layer having enteral coating, pH 6.6-6.95. Also, invention relates to a method for preparing the composition wherein layers are applied in a device used for applying coatings in moving layer. Proposed compositions elicit the enhanced stability and biological availability.

EFFECT: improved and valuable pharmaceutical properties of compositions.

15 cl, 2 ex

FIELD: medicine, endocrinology, pharmacy.

SUBSTANCE: invention relates to medicinal agents, in particular, to the hormonal pharmaceutical composition. Invention proposes new pharmaceutical compositions and a method for preparing such compositions formed by the estrogen-gestagen combination with a single gestagen compound in mixture with one or some nontoxic, inert pharmaceutically acceptable carriers designated for oral administration. Also, invention relates to the estrogen-gestagen mixture wherein estrogenic component and gestagenic component are used by the combined method. Proposed composition is designated for treatment of estrogenic insufficiency, prophylaxis of osteoporosis and cardiovascular diseases in women in the menopause period. Invention provides the development of the new estrogen-gestagen combination showing activity in the oral route of applying and administrated by the combined method.

EFFECT: improved and valuable medicinal properties of composition.

12 cl, 8 tbl, 3 ex

Up!